Therapeutic Class Overview: Treating Refractory Hematological Malignancies

1
(No Transcript)
2
Report THERAPEUTIC CLASS OVERVIEW TREATING
REFRACTORY HEMATOLOGICAL MALIGNANCIES
Report Insights

• Targeting unmet needs in the treatment of cancer
  or hematological malignancies through innovative
  drug development strategies have witnessed
  favorable outcomes
• Over the past decade, Proteasome inhibitor,
  Velcade (bortezomib) and the immunomodulatory
  drugs - Thalomid (thalidomide) and Revlimid
  (lenalidomide) have become the cornerstone of
  treatment for patients with Multiple Myeloma (MM)
  resulting in improved survival
• However, eventually all patients relapse and new
  treatment options for Relapsed/ Refractory
  Multiple Myeloma (RRMM) are required to further
  improve survival and quality of life of this
  group of patients

3
Report THERAPEUTIC CLASS OVERVIEW TREATING
REFRACTORY HEMATOLOGICAL MALIGNANCIES
Report Insights (Continued)

• Two new drugs have successfully fulfilled this
  need - POMALYST/ IMNOVID (pomalidomide - POM) and
  Kyprolis (carfilzomib-CFZ)
• A similar scenario is expected to unfold in the
  treatment of Recurrent/ Refractory MDS (RR-MDS,
  High-Risk MDS), and Relapsed/ Refractory AML (R/R
  AML)
• Innovative approach to treating unmet need has
  been handsomely rewarded in the past through
  in-licensing or outright acquisition of the
  mature or nascent product or innovator company at
  a premium

4
Report THERAPEUTIC CLASS OVERVIEW TREATING
REFRACTORY HEMATOLOGICAL MALIGNANCIES
Report Coverage

• Overview of the approved therapies for RRMM,
  NDMM, AML, MDS, unmet need and limitations of the
  current SOC for relapsed and refractory patients
• Competition and commercial opportunity in
  pursuing these therapy areas
• Comprehensive list of the early and late stage
  drugs in the clinic, their MoA and the companies
  developing them

5
Report THERAPEUTIC CLASS OVERVIEW TREATING
REFRACTORY HEMATOLOGICAL MALIGNANCIES
Table of Contents

• Executive Summary
• Disease Overview MDS and AML
• Current Standard of Care MDS and AML
• Unmet Need AML
• Late-Stage pipeline Targeting High-Risk or R/R
  MDS AND R/R AML
• Late-Stage pipeline Targeting 1st-line Lower Risk
  MD
• Key Milestones of Drugs For RRMDS/RRAML in
  2014-2015
• Launch Timeline and Commercial Opportunity of
  Late-Stage Pipeline (RR MDS and RR AML)
• Drivers of MA/Licensing Deals in MDS/AML

6
Report THERAPEUTIC CLASS OVERVIEW TREATING
REFRACTORY HEMATOLOGICAL MALIGNANCIES
Report Details

• Publish date Feb 22, 2014
• Number of slides 43
• Geographic coverage Global
• Available format PDF, CD, Hardcopy
• Price for Single User License USD 1,500
• Price for Site License USD 3,003
• Price for Global User License USD 4,503
• Delivery Time Within 1 business day
• Payment Modes Credit/Debit Card, RTGS/Wire
  Transfer, Google Wallet, PayPal

7
Interested in this report?
To view more details regarding this premium
market research report, Please click here
For further information, get in touch with us
E-mail support_at_researchonglobalmarkets.com Call
US 1 866 325 7446 UK 44 203 514 2363 Others
91 22 4098 7600
About Us Research on Global Markets is a leading
source for market research on various sectors
globally offering premium research content from
worldwide publishers of market research reports
Industry Segments Industry Segments Industry Segments
Automotive Transport Consumer goods Agriculture
Food and Beverage Energy and Utilities Public Sector
Manufacturing Construction Healthcare Media Entertainment
IT, Telecom Electronics Services Others